|
US11529347B2
(en)
|
2016-09-22 |
2022-12-20 |
Relay Therapeutics, Inc. |
SHP2 phosphatase inhibitors and methods of use thereof
|
|
TW202500565A
(zh)
|
2016-10-24 |
2025-01-01 |
美商傳達治療有限公司 |
Shp2磷酸酶抑制劑及其使用方法
|
|
MX2019008695A
(es)
|
2017-01-23 |
2019-09-11 |
Revolution Medicines Inc |
Compuestos biciclicos como inhibidores alostericos de shp2.
|
|
MX2019008696A
(es)
|
2017-01-23 |
2019-09-13 |
Revolution Medicines Inc |
Compuestos de piridina como inhibidores de shp2 alostericos.
|
|
WO2018218133A1
(en)
|
2017-05-26 |
2018-11-29 |
Relay Therapeutics, Inc. |
Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
|
|
CA3074690A1
(en)
|
2017-09-07 |
2019-03-14 |
Revolution Medicines, Inc. |
Shp2 inhibitor compositions and methods for treating cancer
|
|
EP3687997A1
(en)
|
2017-09-29 |
2020-08-05 |
Relay Therapeutics, Inc. |
Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
|
|
MX2020003579A
(es)
|
2017-10-12 |
2020-07-22 |
Revolution Medicines Inc |
Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos.
|
|
BR112020009757A2
(pt)
*
|
2017-12-15 |
2020-11-03 |
Revolution Medicines, Inc. |
compostos policíclicos como inibidores alostéricos de shp2
|
|
WO2019183364A1
(en)
|
2018-03-21 |
2019-09-26 |
Relay Therapeutics, Inc. |
Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof
|
|
SG11202009245TA
(en)
|
2018-03-21 |
2020-10-29 |
Relay Therapeutics Inc |
Shp2 phosphatase inhibitors and methods of use thereof
|
|
WO2020072656A1
(en)
|
2018-10-03 |
2020-04-09 |
Gilead Sciences, Inc. |
Imidozopyrimidine derivatives
|
|
CN111138412B
(zh)
|
2018-11-06 |
2023-09-15 |
上海奕拓医药科技有限责任公司 |
一种螺芳环化合物及其应用
|
|
CN113272303B
(zh)
*
|
2018-11-30 |
2024-09-17 |
上海拓界生物医药科技有限公司 |
嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
|
|
AU2020306124A1
(en)
*
|
2019-06-28 |
2022-02-03 |
Tuojie Biotech (Shanghai) Co., Ltd. |
Pyrimidine five-membered nitrogen heterocyclic derivative, preparation method thereof and pharmaceutical use thereof
|
|
CN111704611B
(zh)
*
|
2019-07-25 |
2022-01-14 |
上海凌达生物医药有限公司 |
一类芳基螺环类shp2抑制剂化合物、制备方法和用途
|
|
CN112300160A
(zh)
*
|
2019-08-01 |
2021-02-02 |
上海奕拓医药科技有限责任公司 |
一种螺芳环化合物、其制备及应用
|
|
EP3772513A1
(en)
|
2019-08-09 |
2021-02-10 |
C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening |
Shp2 inhibitors
|
|
AU2020354475A1
(en)
|
2019-09-24 |
2022-05-05 |
Relay Therapeutics, Inc. |
SHP2 phosphatase inhibitors and methods of making and using the same
|
|
WO2021088945A1
(zh)
*
|
2019-11-08 |
2021-05-14 |
南京圣和药业股份有限公司 |
作为shp2抑制剂的化合物及其应用
|
|
CN113754683A
(zh)
*
|
2020-06-05 |
2021-12-07 |
上海奕拓医药科技有限责任公司 |
同位素取代的螺芳环化合物及其应用
|
|
EP4169920A4
(en)
*
|
2020-06-18 |
2024-08-07 |
Etern Biopharma (Shanghai) Co., Ltd. |
CRYSTALLINE FORM OF A SHP2 INHIBITOR AND COMPOSITION THEREOF, METHOD OF PREPARING THE SAME AND USE THEREOF
|
|
IL299131A
(en)
|
2020-06-18 |
2023-02-01 |
Revolution Medicines Inc |
Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
|
|
MX2023002248A
(es)
|
2020-09-03 |
2023-05-16 |
Revolution Medicines Inc |
Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
|
|
MX2023003060A
(es)
|
2020-09-15 |
2023-04-05 |
Revolution Medicines Inc |
Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
|
|
CN114380845B
(zh)
*
|
2020-10-19 |
2025-06-20 |
四川科伦博泰生物医药股份有限公司 |
一种并杂环类化合物，包含其的药物组合物，其制备方法及其用途
|
|
CN114478585A
(zh)
*
|
2020-10-26 |
2022-05-13 |
上海青煜医药科技有限公司 |
含氮稠杂环类化合物及其制备方法和应用
|
|
WO2022089389A1
(zh)
*
|
2020-10-30 |
2022-05-05 |
赣江新区博瑞创新医药有限公司 |
杂环化合物及其制备方法、药物组合物和应用
|
|
WO2022135568A1
(zh)
*
|
2020-12-25 |
2022-06-30 |
江苏恒瑞医药股份有限公司 |
一种嘧啶并五元氮杂环类衍生物的晶型及其制备方法
|
|
AU2022217319A1
(en)
*
|
2021-02-05 |
2023-08-17 |
Hutchmed Limited |
Tricyclic compounds and uses thereof
|
|
WO2022235866A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
AU2022268962A1
(en)
|
2021-05-05 |
2023-12-14 |
Revolution Medicines, Inc. |
Ras inhibitors for the treatment of cancer
|
|
CA3217393A1
(en)
|
2021-05-05 |
2022-11-10 |
Elena S. Koltun |
Ras inhibitors
|
|
CN115304612A
(zh)
*
|
2021-05-08 |
2022-11-08 |
南京圣和药业股份有限公司 |
杂环类shp2抑制剂的晶型
|
|
CN115304613A
(zh)
*
|
2021-05-08 |
2022-11-08 |
南京圣和药业股份有限公司 |
杂环类shp2抑制剂的制备方法
|
|
WO2022259157A1
(en)
|
2021-06-09 |
2022-12-15 |
Novartis Ag |
A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor
|
|
TW202317100A
(zh)
|
2021-06-23 |
2023-05-01 |
瑞士商諾華公司 |
包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
|
|
TW202328133A
(zh)
*
|
2021-08-27 |
2023-07-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
Shp2抑制劑治療含有ras通路基因突變的腫瘤的用途
|
|
CA3224341A1
(en)
|
2021-09-01 |
2023-03-09 |
Novartis Ag |
Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
EP4227307A1
(en)
*
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
CN119136806A
(zh)
|
2022-03-08 |
2024-12-13 |
锐新医药公司 |
用于治疗免疫难治性肺癌的方法
|
|
CN117003772B
(zh)
*
|
2022-04-28 |
2026-02-27 |
博瑞生物医药（苏州）股份有限公司 |
杂环化合物的可药用盐及其晶型、制备方法和用途
|
|
WO2023220703A1
(en)
*
|
2022-05-12 |
2023-11-16 |
Genentech, Inc. |
Methods and compositions comprising a shp2 inhibitor and a pd-l1 binding antagonist
|
|
CN114920759B
(zh)
*
|
2022-05-18 |
2024-09-10 |
江南大学 |
杂环-三氮唑并噻二唑杂环串联化合物、合成方法、药物组合物及用途
|
|
CN117209500B
(zh)
*
|
2022-06-01 |
2026-04-10 |
上海凌达生物医药有限公司 |
Shp2抑制剂、其晶型及其制备方法与用途
|
|
WO2023230968A1
(zh)
*
|
2022-06-01 |
2023-12-07 |
上海凌达生物医药有限公司 |
Shp2抑制剂、其晶型及其制备方法与用途
|
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
WO2024125603A1
(zh)
*
|
2022-12-15 |
2024-06-20 |
江苏威凯尔医药科技有限公司 |
Shp2抑制剂及其应用
|
|
EP4687905A1
(en)
|
2023-03-30 |
2026-02-11 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
KR20260005904A
(ko)
|
2023-04-07 |
2026-01-12 |
레볼루션 메디슨즈, 인크. |
매크로사이클릭 ras 억제제
|
|
CN121263418A
(zh)
|
2023-04-07 |
2026-01-02 |
锐新医药公司 |
大环ras抑制剂
|
|
KR20250172857A
(ko)
|
2023-04-14 |
2025-12-09 |
레볼루션 메디슨즈, 인크. |
Ras 억제제의 결정형
|
|
AU2024252105A1
(en)
|
2023-04-14 |
2025-10-16 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|
|
AU2024265078A1
(en)
|
2023-05-04 |
2025-12-11 |
Revolution Medicines, Inc. |
Combination therapy for a ras related disease or disorder
|
|
IL326136A
(en)
|
2023-08-07 |
2026-03-01 |
Revolution Medicines Inc |
RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
|
|
US20250154171A1
(en)
|
2023-10-12 |
2025-05-15 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|